Liu, A;
Hammond, R;
Chan, K;
Chukwuenweniwe, C;
Johnson, R;
Khair, D;
Duck, E;
Olubodun, O;
Barwick, K;
Banya, W;
et al.
Liu, A; Hammond, R; Chan, K; Chukwuenweniwe, C; Johnson, R; Khair, D; Duck, E; Olubodun, O; Barwick, K; Banya, W; Stirrup, J; Donnelly, PD; Kaski, JC; Coates, ARM
(2023)
Comparison of Lymphocyte–CRP Ratio to Conventional Inflammatory Markers for Predicting Clinical Outcomes in COVID-19.
Journal of Personalized Medicine, 13 (6).
p. 909.
ISSN 2075-4426
https://doi.org/10.3390/jpm13060909
SGUL Authors: Coates, Anthony Robert Milnes
|
PDF
Published Version
Available under License Creative Commons Attribution. Download (2MB) | Preview |
Abstract
Background: In COVID-19 patients, lymphocyte–CRP ratio (LCR) is a promising biomarker for predicting adverse clinical outcomes. How well LCR performs compared to conventional inflammatory markers for prognosticating COVID-19 patients remains unclear, which hinders the clinical translation of this novel biomarker. Methods: In a cohort of COVID-19 inpatients, we characterised the clinical applicability of LCR by comparing its prognostic value against conventional inflammatory markers for predicting inpatient mortality and a composite of mortality, invasive/non-invasive ventilation and intensive care unit admissions. Results: Of the 413 COVID-19 patients, 100 (24%) patients suffered inpatient mortality. On Receiver Operating Characteristics analysis, LCR performed similarly to CRP for predicting mortality (AUC 0.74 vs. 0.71, p = 0.049) and the composite endpoint (AUC 0.76 vs. 0.76, p = 0.812). LCR outperformed lymphocyte counts (AUC 0.74 vs. 0.66, p = 0.002), platelet counts (AUC 0.74 vs. 0.61, p = 0.003) and white cell counts (AUC 0.74 vs. 0.54, p < 0.001) for predicting mortality. On Kaplan–Meier analysis, patients with a low LCR (below a 58 cut-off) had worse inpatient survival than patients with other LCR values (p < 0.001). Conclusion: LCR appears comparable to CRP, but outperformed other inflammatory markers, for prognosticating COVID-19 patients. Further studies are required to improve the diagnostic value of LCR to facilitate clinical translation.
Item Type: | Article |
---|---|
Additional Information: | © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
SGUL Research Institute / Research Centre: | Academic Structure > Infection and Immunity Research Institute (INII) |
Journal or Publication Title: | Journal of Personalized Medicine |
ISSN: | 2075-4426 |
Language: | en |
Publisher License: | Creative Commons: Attribution 4.0 |
URI: | https://openaccess.sgul.ac.uk/id/eprint/115440 |
Publisher's version: | https://doi.org/10.3390/jpm13060909 |
Statistics
Actions (login required)
![]() |
Edit Item |